Analysts Downgrade 4 Healthcare Stocks as December Trading Comes to Close

Wall St. Watchdog reveals information about companies for which stock analysts downgraded shares in the Healthcare sector for the week ending December 23rd, 2011.

Eli Lilly (NYSE:LLY): MKM Partners downgraded its rating on this company to Sell and changed its price target to $33 on Dec 20th. The shares recently traded at $41.64, up $0.52, or 1.26% since the analyst’s rating. About the company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products. Get the most recent company news and stock data here >>

ZELTIQ Aesthetics (NASDAQ:ZLTQ): William Blair downgraded its rating on this company to Outperform on Dec 20th. The shares recently traded at $11.46, down $0.32, or 2.72% since the analyst’s rating. About the company: Zeltiq Aesthetics Inc. provides medical services. The Company offers design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. Get the most recent company news and stock data here >>

Dexcom (NASDAQ:DXCM): MLV & Co downgraded its rating on this company to Buy and changed its price target to $11 on Dec 20th. The shares recently traded at $8.58, down $0.03, or 0.35% since the analyst’s rating. About the company: DexCom Inc. is a medical device company focused on the design and development of continuous glucose monitoring systems for people with diabetes. The Company has developed a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin, and a small external receiver to which the sensor transmits glucose levels at specified intervals. Get the most recent company news and stock data here >>

Boston Scientific (NYSE:BSX): Mizuho downgraded its rating on this company from Buy to Neutral and changed its price target from $7 to $5.4 on Dec 22nd. About the company: Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company’s products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com